Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 71.93%-313K | -3,849.54%-598.09K | 56.07%-2.35M | 14.12%-1.54M | 141.09%296.02K | 32.63%-1.11M | 101.37%15.95K | -42.59%-5.34M | -1.8M | -720.48K |
| Net income from continuing operations | 62.98%-422.33K | 73.63%-424.67K | 46.32%-4.3M | 23.45%-1.22M | 86.45%-329.02K | 36.47%-1.14M | 26.45%-1.61M | -79.71%-8M | ---1.59M | ---2.43M |
| Depreciation and amortization | -35.45%46.01K | -34.76%48.49K | 9.71%276.66K | -9.69%62.6K | 2.00%68.45K | 20.21%71.28K | 31.67%74.33K | 85.59%252.17K | --69.32K | --67.1K |
| Asset impairment expenditure | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Remuneration paid in stock | -56.22%52.45K | -57.12%90.09K | -72.23%472.4K | 38.71%35K | -88.54%107.52K | -57.35%119.79K | -54.05%210.08K | 57.24%1.7M | --25.24K | --937.99K |
| Other non cashItems | -104.03%-154 | 1,019.51%918 | 144.63%54.28K | 1,995.32%47K | -24.34%3.38K | -42.58%3.82K | -99.07%82 | 2,207.03%22.19K | --2.24K | --4.46K |
| Change In working capital | 106.52%11.03K | -123.32%-312.92K | 67.55%1.15M | -54.36%-473.42K | -36.10%446.06K | 17.98%-169.06K | 169.29%1.34M | 231.78%683.49K | ---306.7K | --698.1K |
| -Change in receivables | -387.66%-904.54K | 58.73%264.33K | -72.25%-1.1M | 50.71%-274.69K | -360.67%-1.31M | 156.51%314.45K | 711.50%166.53K | -96.56%-639.31K | ---557.27K | --501.6K |
| -Change in inventory | -323.31%-122.61K | 2,059.11%1.09M | -410.27%-577.25K | -482.44%-863.66K | -39.56%180.86K | -66.23%54.91K | 139.73%50.64K | -35.56%186.05K | ---148.28K | --299.23K |
| -Change in prepaid assets | 191.64%536.86K | -127.03%-69.37K | -199.35%-460.88K | -382.36%-403.84K | 155.87%272.18K | -1,702.85%-585.86K | 3.90%256.64K | 155.88%463.91K | --143.03K | --106.37K |
| -Change in payables and accrued expense | 301.22%1.28M | -680.31%-663.62K | 151.03%1.19M | -245.64%-423.96K | 524.86%1.18M | 198.79%319.98K | -67.62%114.36K | 45.98%473.81K | --291.11K | ---277.51K |
| -Change in other working capital | -187.13%-782.52K | -224.46%-937.7K | 952.65%2.1M | 4,330.85%1.49M | 77.59%121.48K | -340.89%-272.54K | 1,327.61%753.43K | 749.08%199.03K | ---35.28K | --68.4K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 71.93%-313K | -3,849.54%-598.09K | 56.07%-2.35M | 14.10%-1.54M | 141.14%296.38K | 32.63%-1.11M | 101.37%15.95K | -42.59%-5.34M | ---1.8M | ---720.48K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 39.15%-21.76K | 0 | -29.67%-47.25K | -111.70%-1.36K | 112.87%8.09K | -658.50%-35.76K | -316.46%-18.22K | -294.99%-36.44K | 11.59K | -62.84K |
| Net PPE purchase and sale | 39.15%-21.76K | --0 | 54.77%-85.27K | 94.87%-1.36K | 108.02%8.09K | -13.09%-35.76K | -89.98%-56.25K | -391.62%-188.54K | ---26.44K | ---100.87K |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Net other investing changes | ---- | ---- | -75.00%38.03K | --0 | --0 | --0 | 0.00%38.03K | 166.67%152.1K | --38.03K | --38.03K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 39.15%-21.76K | --0 | -29.67%-47.25K | -111.70%-1.36K | 112.87%8.09K | -658.50%-35.76K | -316.46%-18.22K | -294.99%-36.44K | --11.59K | ---62.84K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 59.26%-17.69K | 1,562.59%806.21K | -85.06%775.41K | 1,268.60%917.61K | 43.52%-43.66K | 20.00%-43.42K | -101.02%-55.12K | 1,465.46%5.19M | -78.52K | -77.3K |
| Net issuance payments of debt | 59.26%-17.69K | 40.43%-32.84K | 29.31%-219.1K | 2.07%-76.9K | 43.52%-43.66K | 43.66%-43.42K | 28.48%-55.12K | -58.65%-309.96K | ---78.52K | ---77.3K |
| Net common stock issuance | --0 | --839.05K | -79.78%994.51K | --994.51K | --0 | --0 | --0 | --4.92M | --0 | --0 |
| Proceeds from stock option exercised by employees | ---- | ---- | --0 | --0 | --0 | --0 | --0 | 1,232.02%582.41K | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 59.26%-17.69K | 1,562.59%806.21K | -85.06%775.41K | 1,268.60%917.61K | 43.52%-43.66K | 20.00%-43.42K | -101.02%-55.12K | 1,465.46%5.19M | ---78.52K | ---77.3K |
| Net cash flow | ||||||||||
| Beginning cash position | -55.18%1.09M | -65.46%862.5K | -7.04%2.5M | -65.89%1.49M | -76.10%1.25M | -64.78%2.44M | -7.04%2.5M | -60.46%2.69M | --4.37M | --5.22M |
| Current changes in cash | 70.48%-352.45K | 462.62%208.12K | -770.48%-1.62M | 67.86%-599.12K | 126.99%232.25K | 29.88%-1.19M | -101.35%-57.39K | 95.47%-185.92K | ---1.86M | ---860.62K |
| Effect of exchange rate changes | -284.91%-4.98K | 26,746.51%22.92K | -409.48%-16.18K | -346.80%-28.06K | 67.47%9.28K | 231.14%2.69K | 77.55%-86 | ---3.18K | ---6.28K | --5.54K |
| End cash Position | -41.02%736.11K | -55.18%1.09M | -65.46%862.5K | -65.46%862.5K | -65.89%1.49M | -76.10%1.25M | -64.78%2.44M | -7.04%2.5M | --2.5M | --4.37M |
| Free cash from | 70.91%-334.76K | -1,384.24%-598.09K | 56.02%-2.43M | 15.27%-1.55M | 137.07%304.47K | 31.77%-1.15M | 96.64%-40.3K | -46.12%-5.53M | ---1.82M | ---821.35K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.